Skip to main content

Volume 8 Supplement 1

Coartem®: reviewing the impact on the malaria landscape


Edited by Marcel Hommel

Publication of this supplement has been sponsored by Novartis Pharma AG.

  1. Artemisinin, from which the artemether component of Coartem®(artemether/lumefantrine, AL) is derived, is obtained from the plant sweet wormwood (Artemisia annua) which has been used for over 2,000 years as a Chin...

    Authors: Zulfiqarali G Premji
    Citation: Malaria Journal 2009 8(Suppl 1):S3
  2. Artemether and lumefantrine (AL), the active constituents of Coartem® exhibit complementary pharmacokinetic profiles. Artemether is absorbed quickly; peak concentrations of artemether and its main active metaboli...

    Authors: Abdoulaye Djimdé and Gilbert Lefèvre
    Citation: Malaria Journal 2009 8(Suppl 1):S4
  3. Current World Health Organization (WHO) guidelines for the treatment of uncomplicated falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/lumefantrine is an ACT preq...

    Authors: Michael Makanga and Srivicha Krudsood
    Citation: Malaria Journal 2009 8(Suppl 1):S5
  4. This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or independently-sponsored clini...

    Authors: Catherine Falade and Christine Manyando
    Citation: Malaria Journal 2009 8(Suppl 1):S6
  5. Malaria is one of the most significant causes of morbidity and mortality worldwide. Every year, nearly one million deaths result from malaria infection. Malaria can be controlled in endemic countries by using ...

    Authors: Karen I Barnes, Pascalina Chanda and Gebre Ab Barnabas
    Citation: Malaria Journal 2009 8(Suppl 1):S8

Annual Journal Metrics

  • 2022 Citation Impact
    3.0 - 2-year Impact Factor
    3.2 - 5-year Impact Factor
    1.148 - SNIP (Source Normalized Impact per Paper)
    1.237 - SJR (SCImago Journal Rank)

    2022 Speed
    11 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    11,190 Altmetric mentions